Examining Drug Trend: Inflammatory Disease

Drug price is driving trend. Overall utilization for the top 10 drug classes in 2016 decreased, while prices increased. To better understand 2016 trend, we will be examining the top 10 therapeutic classes and their trend components. In April, we looked at diabetes. Today, we will examine inflammatory diseases.

Inflammatory Disease
It is no surprise that in 2016, Humira and Enbrel accounted for 68.8 percent of PMPY spend for inflammatory diseases. The third branded agent in inflammatory disease, Stelara, accounted for 5.25 percent of PMPY spend in 2016. One oral agent, Otezla, was the fourth branded agent and accounted for 2.8 percent of PMPY spend.

Forecast: The Promise of Biosimilars
Biosimilars are biologic products that are similar to their reference product, but no guaranteed to be identical. In 2016, the FDA approved Erelizi, a biosimilar to Humira, but neither are currently available on the market. These biosimilars are currently tied up in patient litigation, and will be delayed until 2018 or longer, as indicated by the respective manufacturers.

Psoriasis and Rheumatoid Arthritis
In 2017, more agents are expected to be introduced to the market for Plaque Psoriasis and Rheumatoid Arthritis to compete with current branded agents. Additional JAK inhibitors and biologics targeting IL-23, IL-17 and IL-6 are currently under review for approval at the FDA.

See our 2016 Annual Trend Report to learn more about trend drivers and forecasts for the top therapeutic classes. Make sure to check MedConnect for more in this series.


  • Email